Tuesday, November, 12, 2019 02:44:04

Diploid & Genomenon team up to advance rare disease diagnostics

In a major effort to develop genome interpretation for the rare disease diagnostics, Genomenon, a top genomic research company, and Diploid, a prominent AI-based software company for rare disease diagnostics, have reportedly inked a partnership deal. Sources with the knowledge of the matter stated that …

FDA permits Priority Review for Roche’s drug Polatuzumab Vedotin

The FDA will decide on the definitive approval by the 19th of August 2019. The U.S. Food & Drug Administration (FDA) has reportedly accepted the BLA (Biologics License Application) submitted by the Swiss multinational healthcare company, Roche. The company has been officially granted Priority Review …

Innovent, Chipscreen Biosciences team up on colorectal cancer therapy

Shenzhen Chipscreen Biosciences Ltd., a leading China-based integrated biotech company, has reportedly entered into a collaboration agreement with Innovent Biologics Inc., a Chinese development-stage biopharmaceutical company, in a major effort to evaluate the tolerability and safety of the combination therapy involving Innovent’s Sintilimab and Chipscreen’s …

AbCellera to sign multi-target partnership deal with Novartis

AbCellera Biologics Inc., the antibody therapeutics developer based in Vancouver, has reportedly entered into a multi-year, multi-target partnership agreement with Novartis International AG, the Swiss multinational pharmaceutical company. Reportedly, the agreement entails the identification of antibodies for about ten therapeutic targets in the pipeline of …

GrapheneCA plans graphene production for cosmetics & pharma sectors

Nano Graphene Inc. (also known as GrapheneCA), a US-based supplier of graphene-based materials, has reportedly announced its plans to make graphene readily available for use in the cosmetics and pharmaceutical industries. Reportedly, GrapheneCA’s latest move helps in paving the path for the introduction & licensing …